title: Analysis of the relationship between chimerism and the allgeneic humoral response.
abstract: BACKGROUND
  Persistence of antigens has been suggested to play a role in two opposing immunological phenomena: tolerance and memory. Therefore, we studied the impact of chimerism on alloreactive antibody (allo-Ab) production in kidney transplant patients.
  
  
  METHODS
  Thirty-five female renal transplant recipients of male donor organs were classified into the following groups: group 1, 13 sensitized uremic patients on dialysis; group 2, 5 nonsensitized uremic patients on dialysis; group 3, six sensitized patients experiencing graft rejection (3 acute vascular, 1 acute cellular, and 2 chronic); and group 4, 11 nonsensitized with functioning allografts (9 with good function, 1 with acute cellular rejection, and 1 with chronic rejection). Mean duration of dialysis after graft failure was similar in groups 1 (56+/-29.7 months) and 2 (41.8+/-42.4 months), as was dialysis efficiency. Chimerism was measured indirectly in the peripheral blood lymphocytes by polymerase chain reaction amplification of a specific Y chromosome DNA gene sequence with a detection sensitivity limit of 1 male cell per 1 million female cells. Allo-Ab production was measured by the PRA-STAT enzyme-linked immunosorbent assay (Sangstat) method.
  
  
  RESULTS
  Chimerism was observed in 60% of groups 1 and 2, 83% of group 3, and 82% of group 4. Among all groups, graft existence, irrespective of its function, positively predicted chimerism in 92% with a sensitivity of 88% and a specificity of 78%. In group 3, all three patients with acute vascular rejection had chimerism and donor-specific allo-Abs. In group 4, eight of the nine patients with no rejection had chimerism.
  
  
  CONCLUSIONS
  Chimerism relates to persistence of allogeneic stimulus irrespective of its function. Chimerism did not confer protection against allo-Ab production or vascular rejection, and its existence was not crucial for sustenance of allo-Ab production.
authors.affiliation: Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada.
authors.forename: K M
authors.initials: KM
authors.lastname: Okasha
authors.forename: T A
authors.initials: TA
authors.lastname: Al-Tweigeri
authors.forename: A V
authors.initials: AV
authors.lastname: Jurado
authors.forename: A S
authors.initials: AS
authors.lastname: Shoker
mesh_terms: D000328:Adult; D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation / Q000502:physiology; D002678:Chimera / Q000276:immunology*; D005260:Female; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000906:Antibodies; D007518:Isoantibodies